7.18
0.41 (6.06%)
| Penutupan Terdahulu | 6.77 |
| Buka | 6.80 |
| Jumlah Dagangan | 992,826 |
| Purata Dagangan (3B) | 843,560 |
| Modal Pasaran | 358,501,472 |
| Harga / Buku (P/B) | 2.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -4.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.08% |
| Nisbah Semasa (MRQ) | 7.75 |
| Aliran Tunai Operasi (OCF TTM) | -101.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cybin Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.25 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 207.96% |
| % Dimiliki oleh Institusi | 42.41% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |